• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

临床输血与检验 ›› 2019, Vol. 21 ›› Issue (5): 527-530.DOI: 10.3969/j.issn.1671-2587.2019.05.024

• 临床检验 • 上一篇    下一篇

左卡尼汀辅助血液灌流联合血液透析治疗尿毒症对心功能及骨代谢的影响

蒋霞, 陈志伟, 王文娟   

  1. 226002 江苏省南通市第二人民医院肾脏内科
  • 收稿日期:2018-02-06 出版日期:2019-10-20 发布日期:2019-10-29
  • 通讯作者: 陈志伟,男,主治医师,主要从事肾脏内科工作,(E-mail)chenzhiweill@163.com。
  • 作者简介:蒋霞(1976-),女,江苏南通人,副主任医师,学士,主要从事肾脏内科工作,(E-mail)rhilv7@163.com。

Effect of Levocarnitine and Hemoperfusion Combined with Hemodialysis on Cardiac Function and Bone Metabolism in Patients with Uremia

JIANG Xia, CHEN Zhi-wei, WANG wen-juan   

  1. Department of Nephrology,Nantong Second People's Hospital,Jiangsu226002
  • Received:2018-02-06 Online:2019-10-20 Published:2019-10-29

摘要: 目的 探讨左卡尼汀辅助血液灌流联合血液透析治疗尿毒症对患者心功能及骨代谢指标的影响。方法 将本院于2015年1月~2017年12月收治的60例尿毒症患者按随机抽签方式分为2组,各30例。给予对照组血液透析治疗,研究组在对照组基础上采用左卡尼汀辅助血液灌流治疗。比较两组治疗前后心功能指标[左室射血分数(LVEF)、每搏量(SV)、左心室短轴缩短率(FS)、舒张期早期及晚期二尖瓣血流速度E峰与A峰比值(E/A)]、骨代谢指标[骨碱性磷酸酶(BALP)、全段甲状旁腺素(iPTH)]、肾功能指标[尿素氮(BUN)、血清肌酐(Scr)]及不良反应发生情况。结果 治疗后,研究组心功能指标(LVEF、SV、FS、E/A)均明显高于对照组,差异有统计学意义(P<0.05);治疗后,研究组骨代谢指标(BALP、iPTH)、肾功能指标(BUN、Scr)均明显低于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率为6.67%(2/30),明显低于对照组26.67%(8/30),差异有统计学意义(P<0.05)。结论 对尿毒症患者采用左卡尼汀辅助血液灌流联合血液透析治疗,疗效确切,可有效改善患者心功能、肾功能,减少骨代谢异常的发生,且不增加不良反应,值得推广。

关键词: 左卡尼汀, 血液灌流, 血液透析, 尿毒症, 心功能, 骨代谢

Abstract: Objective To investigate the effect of levocarnitine and hemoperfusion combined with hemodialysis on cardiac function and bone metabolism in patients with uremia.Methods 60 patients with uremia admitted into our hospital from January 2015 to December 2017 were divided into two groups by draw lots,with 30 cases in each group. Control group was given hemodialysis,while research group was treated with levocarnitine and hemoperfusion based on control group. The indexes of cardiac function [left ventricular ejection fraction (LVEF),stroke volume (SV),fractional shortening (FS),E/A],indexes of bone metabolism [bone alkaline phosphatase (BALP),intact parathyroid hormone (iPTH)],indexes of renal function [blood urea nitrogen (BUN),serum creatinine (Scr)] and adverse reactions were compared between the two groups.Results After treatment,the indexes of cardiac function (LVEF,SV,FS,E/A) in research group were higher than those in control group (P<0.05); After treatment,the indexes of bone metabolism (BALP,iPTH) and renal function (BUN,Scr) in research group were lower than those in control group (P<0.05); The incidence of adverse reactions in research group was 6.67%(2/30),which was lower than 26.67%(8/30) in control group (P<0.05).Conclusion Levocarnitine and hemoperfusion combined with hemodialysis in treatment of uremia is effective,it can improve cardiac function and renal function,reduce bone metabolism disorder,and not increase adverse reactions,which is worthy of promotion.

Key words: Levocarnitine, Hemoperfusion, Hemodialysis, Uremia, Cardiac function, Bone metabolism

中图分类号: